The Procter Gamble Company

Akebia Therapeutics, Inc.

Eyepoint Pharmaceuticals, Inc.

Wyeth

Aerpio Therapeutics, Inc.

Aerpio Pharmaceuticals, Inc.

Procter & Gamble Pharmaceuticals, Inc.

John M Janusz

Laurence Ichih Wu

Boris Gorin

Jan Oudenes

James Densmore Copp

Craig Edward Dixon

Christopher M Lanthier

Kevin Gene Peters

Thomas R LaHann

Alan Quigbo Lu

John Michael Gardlik

Robert A Shalwitz

Frank Hallock Ebetino

Ronald E White

Benjamin E Blass

Marion David Francis

Stephen Joseph Hodson

Brian Lee Buckwalter

Alexander Smith

Neil Thomas Fairweather

Susan Mary Kaas

Dennis G Nelson

Gregory Kent Bosch

Christopher M Jackson

Bryan Patrick Murphy

Stanislaw Pikul

John August Wos

Joseph H Gardner

Garry Steven Garrett

Shengde Wu

George Peter Rizzi

Gerald B Kasting

Carl R Johnson

Maurice E Loomans

Michael Wiard Scherz

James Denmore Copp

Joseph A Miller

Charlotte Suzanne Hartman

Theresa Rosario-Jansen

Zhuoliang Chen

James Madison Ridgeway, Ii

Robert B Blum

Akshay Buch

Isaiah Shalwitz

James Copp

Alan Qingbo Lu

Chandrawansha Bandara Senanayake

Charlotte Hartman

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for vascular disorders that can include, for example, retinopathies, ocular edema, and ocular neovascularization.

Small molecule activators of Tie-2

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed. Combination therapy with antibodies and PK/PD data are also disclosed.

Compositions, formulations and methods for treating ocular diseases

Provided herein are specific doses of, and dosing regimens for, using a HIF prolyl hydroxylase inhibitor in treating or preventing anemia, such as anemia secondary to or associated with chronic kidney disease, anemia associated with or resulting from chemotherapy, or anemia associated with AIDS.

Compositions and methods for treating anemia

Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.

Process for preparing [(3-hydroxypyridine-2-carbonyl)amino]alkanoic acids, esters and amides

Disclosed herein are compounds effective for activation of Tie-2 and inhibition of HPTP-beta. The compounds can provide effective therapy for conditions associated with angiogenesis, for example, ocular conditions. Formulations for increased solubility are disclosed.

HPTP-Beta inhibitors

Process for preparing [(3-hydroxypyridine-2-carbonyl)amino] alkanoic acids, esters and amides

HPTP-&#x3b2; inhibitors

Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, {[(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibittors or for treating conditions wherein prolyl hydroxylase inhibition is desired.

A process for synthesizing 2-methoxymethyl-1,4-benzenediamine, its derivatives of formula (IV) and the salts thereof, which comprises a reductive amination step. The preferred final product is 2-methoxymethyl-1,4-benzenediamine of formula (IV-a).  These compounds may be used as primary intermediates in compositions for dyeing keratin fibers.

Process for the preparation of 2-methoxymethy1-1,4-benzenediamine, its derivatives thereof and the salts thereof

The present invention relates to 1-N-amino-2-imidazolidinones and derivatives thereof which are effective as Kv1.5 potassium channel inhibitors providing atrial-selective antiarrhythmic agents. The present invention further relates to compositions comprising said Kv1.5 potassium channel inhibitors, and to methods for treating cardiac arrhythmia.

Kv1.5 potassium channel inhibitors

Growing community of inventors

Fairfield, OH, United States of America

John M Janusz